1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Analysis & Statistics in Oceania Countries, May 2014 (p7)

Pharmaceutical Analysis & Statistics in Oceania Countries, May 2014 (p7)

181-210 of about 200 reports

Purchase Reports From Reputable Market Research Publishers

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
Australia Cardiovascular Procedures Outlook to 2020

Australia Cardiovascular Procedures Outlook to 2020

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Australia Cardiovascular Procedures Outlook to 2020 Summary GlobalData’s new report, "Australia Cardiovascular Procedures Outlook to 2020", provides key procedures data on the Australia Cardiovascula ...

  • Industries : Medical Device, General Medicine and Specialty Medicine, Cardiovascular Devices, Patient Monitoring Device, Healthcare
  • Countries : Australia, Oceania
Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Therapy
  • Countries : World, Australia, Japan
Australia Cardiac Rhythm Management Market Outlook to 2020

Australia Cardiac Rhythm Management Market Outlook to 2020

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Australia Cardiac Rhythm Management Market Outlook to 2020 Summary GlobalData’s new report, "Australia Cardiac Rhythm Management Market Outlook to 2020", provides key market data on the Australia Cardiac ...

  • Industries : Patient Monitoring Device
  • Countries : Australia
New Zealand Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

New Zealand Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

Summary New Zealand Pharmaceuticals Ltd. (NZ Pharma) is a biotechnology service provider. The company extracts and purifies biochemicals from by-products of the New Zealand meat processing industry. Its ...

  • Industries : Pharmaceutical
  • Countries : New Zealand
Phosphagenics Limited : Ingredients - Company Profile, SWOT and Financial Report

Phosphagenics Limited : Ingredients - Company Profile, SWOT and Financial Report

  • $ 125
  • Company report
  • May 2014
  • by Canadean Ltd

Synopsis Canadean's "Phosphagenics Limited : Ingredients - Company Profile, SWOT & Financial Report" contains in depth information and data about the company and its operations. The profile contains a ...

  • Countries : Australia, Japan
Pharmaceuticals in New Zealand

Pharmaceuticals in New Zealand

  • $ 350
  • Industry report
  • April 2014
  • by MarketLine

Introduction Pharmaceuticals in New Zealand industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2009-13, and forecast to 2018). ...

  • Industries : Pharmaceutical, Therapy
  • Countries : New Zealand
Ego Pharmaceuticals Pty Ltd in Consumer Health (Australia)

Ego Pharmaceuticals Pty Ltd in Consumer Health (Australia)

  • $ 143
  • Company report
  • April 2014
  • by Euromonitor International

Ego Pharmaceuticals will continue to reinforce its dominant position in Australia while focusing on expansion within the Asia-Pacific region, the Middle East and the UK to drive additional value growth. ...

  • Industries : Pharmaceutical
  • Countries : Australia
Swisse Vitamins Pty Ltd in Consumer Health (Australia)

Swisse Vitamins Pty Ltd in Consumer Health (Australia)

  • $ 143
  • Company report
  • April 2014
  • by Euromonitor International

Swisse Vitamins Pty Ltd looks to continue its rapid expansion through focusing on international markets and continuing its strategy of engaging high profile brand ambassadors. Swisse has already ventured ...

  • Industries : OTC
  • Countries : Australia
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) ...

  • Industries : Therapy, Biopharmaceutical
  • Countries : Australia
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

  • $ 4 995
  • Industry report
  • March 2014
  • by GBI Research

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability Summary GBI Research, the leading business intelligence ...

  • Industries : Mental Health, General Medicine and Specialty Medicine, Therapy, Pathology
  • Countries : Asia, India, China, Japan, Australia
Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report

Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report

  • $ 965
  • Industry report
  • February 2014
  • by Ibisworld

Man's best friend: Increasing expenditure on companion animals will drive revenue growth Veterinary Pharmaceutical Manufacturing in Australia This industry is mainly engaged in manufacturing drugs, medicines, ...

  • Industries : Veterinary Healthcare
  • Countries : Australia
Vitamin and Supplement Manufacturing in Australia - Industry Market Research Report

Vitamin and Supplement Manufacturing in Australia - Industry Market Research Report

  • $ 965
  • Industry report
  • February 2014
  • by Ibisworld

Healthy and functional: Health awareness and product innovation are driving industry growth Vitamin and Supplement Manufacturing in Australia Vitamin and supplement manufacturers primarily develop and ...

  • Industries : OTC
  • Countries : Australia
Orphan Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Orphan Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary Orphan Australia Pty Ltd (Orphan Australia) is a pharmaceutical company. The company provides novel therapies for the treatment of serious or life-threatening diseases in Australia and New Zealand. ...

  • Industries : Pharmaceutical
  • Countries : Australia
Pharmaceuticals in Australia: ISIC 2423

Pharmaceuticals in Australia: ISIC 2423

  • $ 657
  • Industry report
  • January 2014
  • by Euromonitor International

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at ...

  • Industries : Pharmaceutical
  • Countries : Australia
Healthcare and Pharmaceuticals Report New Zealand 2013

Healthcare and Pharmaceuticals Report New Zealand 2013

  • $ 190
  • Industry report
  • November 2013
  • by The Economist Intelligence Unit

Disease trends;Healthcare;Healthcare;Healthcare;Pharmaceuticals and biotechnology;Healthcare;Spending and provision NCAIS: 62 SIC: 80

  • Industries : Healthcare
  • Countries : New Zealand
Therapy Class Overview : Hepatitis C Virus Infection

Therapy Class Overview : Hepatitis C Virus Infection

  • $ 1 000
  • Industry report
  • October 2013
  • by MP Advisors

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free ...

  • Industries : Therapy
  • Countries : Asia, Australia, China, Taiwan, World, Vietnam, India, Pakistan, Egypt, Saudi Arabia, Syrian Arab Republic
Healthcare and Pharmaceuticals Report Australia August 2013

Healthcare and Pharmaceuticals Report Australia August 2013

  • $ 190
  • Industry report
  • August 2013
  • by The Economist Intelligence Unit

Disease trends;Healthcare;Healthcare;Healthcare;Pharmaceuticals and biotechnology;Healthcare;Spending and provision NCAIS: 62 SIC: 80

  • Industries : Healthcare
  • Countries : Australia
Ear Care in New Zealand

Ear Care in New Zealand

  • $ 992
  • Industry report
  • July 2013
  • by Euromonitor International

Ear care value sales increased by 2% in 2012, which is lower than the 2011 growth of 33%. This is also compared with the current value review period CAGR of 8%. Higher growth in 2011 and over the review ...

  • Industries : OTC
  • Countries : New Zealand
Emergency Contraception in New Zealand

Emergency Contraception in New Zealand

  • $ 992
  • Industry report
  • July 2013
  • by Euromonitor International

Emergency contraception continued to be an acceptable medical method of preventing pregnancy within New Zealand during 2012. While abortion services are provided for free within New Zealand for permanent ...

  • Industries : OTC
  • Countries : New Zealand
OTC Triptans in New Zealand

OTC Triptans in New Zealand

  • $ 992
  • Industry report
  • July 2013
  • by Euromonitor International

During 2012 there were only two OTC triptan products available in New Zealand, Sumagran Active (Mylan New Zealand) and Zomig (AstraZeneca). Several other prescription products were available, such as Maxalt ...

  • Industries : OTC
  • Countries : New Zealand
Go Healthy New Zealand Ltd in Consumer Health (New Zealand)

Go Healthy New Zealand Ltd in Consumer Health (New Zealand)

  • $ 143
  • Company report
  • July 2013
  • by Euromonitor International

Go Healthy New Zealand is interested in providing quality vitamins and dietary supplements to New Zealand consumers. The company also focuses on introducing innovative products that suit consumer needs. ...

  • Industries : OTC, Healthcare
  • Countries : New Zealand
Douglas Pharmaceuticals Ltd in Consumer Health (New Zealand)

Douglas Pharmaceuticals Ltd in Consumer Health (New Zealand)

  • $ 143
  • Company report
  • July 2013
  • by Euromonitor International

By focusing on low-volume high-value products, Douglas Pharmaceuticals continues to attract consumers and expand its operations. Douglas Pharmaceuticals focuses on generic as well as difficult to manufacture ...

  • Industries : Pharmaceutical
  • Countries : New Zealand
Mylan New Zealand Ltd in Consumer Health (New Zealand)

Mylan New Zealand Ltd in Consumer Health (New Zealand)

  • $ 143
  • Company report
  • July 2013
  • by Euromonitor International

Over the forecast period Mylan New Zealand Ltd will focus on its core business of manufacturing and distributing pharmaceutical prescription and OTC consumer health products. Euromonitor International ...

  • Industries : Pharmaceutical, Healthcare
  • Countries : New Zealand
ICT budget forecasts in Small New Zealand Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013

ICT budget forecasts in Small New Zealand Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013

  • $ 495
  • Industry report
  • July 2013
  • by Kable

Synopsis This report illustrates how Kable expects Small New Zealand Pharmaceutical Companies to allocate their ICT budgets across the core areas of enterprise ICT spend, namely hardware, software, IT ...

  • Industries : Pharmaceutical
  • Countries : New Zealand

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.